TY - JOUR AU - Jelkmann, W. PY - 1992 DA - 1992// TI - Erythropoietin: structure, control of production, and function JO - Physiol Rev VL - 72 ID - Jelkmann1992 ER - TY - JOUR AU - Eschbach, J. W. AU - Downing, M. R. AU - Egrie, J. C. AU - Browne, J. K. AU - Adamson, J. W. PY - 1989 DA - 1989// TI - USA multicenter clinical trial with recombinant human erythropoietin (Amgen). Results in hemodialysis patients JO - Contrib Nephrol VL - 76 UR - https://doi.org/10.1159/000417892 DO - 10.1159/000417892 ID - Eschbach1989 ER - TY - JOUR AU - Sobota, J. T. PY - 1989 DA - 1989// TI - Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials JO - Contrib Nephrol VL - 76 UR - https://doi.org/10.1159/000417893 DO - 10.1159/000417893 ID - Sobota1989 ER - TY - JOUR AU - Levin, N. W. AU - Lazarus, J. M. AU - Nissenson, A. R. PY - 1993 DA - 1993// TI - National Cooperative rHu Erythropoietin Study in patients with chronic renal failure – an interim report. The National Cooperative rHu Erythropoietin Study Group JO - Am J Kidney Dis VL - 2 UR - https://doi.org/10.1016/0272-6386(93)70176-Y DO - 10.1016/0272-6386(93)70176-Y ID - Levin1993 ER - TY - JOUR AU - Erslev, A. J. AU - Besarab, A. PY - 1997 DA - 1997// TI - Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure JO - Kidney Int VL - 51 UR - https://doi.org/10.1038/ki.1997.91 DO - 10.1038/ki.1997.91 ID - Erslev1997 ER - TY - JOUR AU - Furuland, H. AU - Linde, T. AU - Ahlmen, J. AU - Christensson, A. AU - Strombom, U. AU - Danielson, B. G. PY - 2003 DA - 2003// TI - A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients JO - Nephrol Dial Transplant VL - 18 UR - https://doi.org/10.1093/ndt/18.2.353 DO - 10.1093/ndt/18.2.353 ID - Furuland2003 ER - TY - CHAP AU - Remuzzi, G. AU - Minetti, L. ED - Brenner ED - Rector's PY - 2000 DA - 2000// TI - Hematologic Consequences of Renal Failure BT - The Kidney PB - Philadelphia CY - W.B. Saunders ID - Remuzzi2000 ER - TY - CHAP AU - Luke, R. G. PY - 2004 DA - 2004// TI - Chronic Renal Failure BT - Goldman: Cecil Textbook of Medicine ID - Luke2004 ER - TY - JOUR AU - Zeid, R. l. PY - 2000 DA - 2000// TI - Regulatory and development issues in the demonstration of therapeutic equivalence for multisource biotech-derived pharmaceuticals JO - Drug Information Journal VL - 34 ID - Zeid2000 ER - TY - JOUR AU - Schellekens, H. AU - Ryff, J. C. PY - 2002 DA - 2002// TI - Biogenerics: the off-patent biotech products JO - Trends Pharmacol Sci VL - 23 UR - https://doi.org/10.1016/S0165-6147(00)01967-2 DO - 10.1016/S0165-6147(00)01967-2 ID - Schellekens2002 ER - TY - JOUR AU - Neumayer, H. H. AU - Brockmoller, J. AU - Fritschka, E. AU - Roots, I. AU - Scigalla, P. AU - Wattenberg, M. PY - 1989 DA - 1989// TI - Pharmacokinetics of recombinant human erythropoietin after SC administration and in long-term IV treatment in patients on maintenance hemodialysis JO - Contrib Nephrol VL - 76 UR - https://doi.org/10.1159/000417889 DO - 10.1159/000417889 ID - Neumayer1989 ER - TY - JOUR AU - Salmonson, T. AU - Danielson, B. G. AU - Wikstrom, B. PY - 1990 DA - 1990// TI - The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects JO - Br J Clin Pharmacol VL - 29 UR - https://doi.org/10.1111/j.1365-2125.1990.tb03692.x DO - 10.1111/j.1365-2125.1990.tb03692.x ID - Salmonson1990 ER - TY - JOUR AU - Souillard, A. AU - Audran, M. AU - Bressolle, F. AU - Gareau, R. AU - Duvallet, A. AU - Chanal, J. L. PY - 1996 DA - 1996// TI - Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control JO - Br J Clin Pharmacol VL - 42 UR - https://doi.org/10.1046/j.1365-2125.1996.41911.x DO - 10.1046/j.1365-2125.1996.41911.x ID - Souillard1996 ER - TY - JOUR AU - Cheung, W. K. AU - Goon, B. L. AU - Guilfoyle, M. C. AU - Wacholtz, M. C. PY - 1998 DA - 1998// TI - Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects JO - Clin Pharmacol Ther VL - 64 UR - https://doi.org/10.1016/S0009-9236(98)90072-8 DO - 10.1016/S0009-9236(98)90072-8 ID - Cheung1998 ER - TY - JOUR AU - Togawa, A. AU - Tanaka, T. AU - Nagashima, S. AU - Keta, H. AU - Kobayashi, Y. AU - Nishikawa, Y. AU - Yanai, M. AU - Tanaka, H. PY - 2004 DA - 2004// TI - A comparison of the bioequivalence of two formulations of epoetin alfa after subcutaneous injection JO - Br J Clin Pharmacol VL - 58 UR - https://doi.org/10.1111/j.1365-2125.2004.02151.x DO - 10.1111/j.1365-2125.2004.02151.x ID - Togawa2004 ER - TY - JOUR AU - Raftery, M. J. AU - Auinger, M. AU - Hertlova, M. PY - 2000 DA - 2000// TI - Safety and tolerability of a multidose formulation of epoetin beta in dialysis patients. Collaborative Study Group JO - Clin Nephrol VL - 54 ID - Raftery2000 ER - TY - JOUR AU - Chen, M. L. AU - Patnaik, R. AU - Hauck, W. W. AU - Schuirmann, D. J. AU - Hyslop, T. AU - Williams, R. PY - 2000 DA - 2000// TI - An individual bioequivalence criterion: regulatory considerations JO - Statist Med VL - 19 UR - https://doi.org/3.0.CO;2-L DO - 3.0.CO;2-L ID - Chen2000 ER - TY - JOUR AU - Chen, M. L. AU - Lesko, L. J. PY - 2001 DA - 2001// TI - Individual bioequivalence revisited JO - Clin Pharmacokinet VL - 40 UR - https://doi.org/10.2165/00003088-200140100-00001 DO - 10.2165/00003088-200140100-00001 ID - Chen2001 ER - TY - JOUR AU - Kampf, D. AU - Kahl, A. AU - Passlick, J. AU - Pustelnik, A. AU - Eckardt, K. U. AU - Ehmer, B. AU - Jacobs, C. AU - Baumelou, A. AU - Grabensee, B. AU - Gahl, G. M. PY - 1989 DA - 1989// TI - Single-dose kinetics of recombinant human erythropoietin after intravenous, subcutaneous and intraperitoneal administration. Preliminary results JO - Contrib Nephrol VL - 76 UR - https://doi.org/10.1159/000417886 DO - 10.1159/000417886 ID - Kampf1989 ER - TY - JOUR AU - Macdougall, I. C. AU - Roberts, D. E. AU - Neubert, P. AU - Dharmasena, A. D. AU - Coles, G. A. AU - Williams, J. D. PY - 1989 DA - 1989// TI - Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis JO - Lancet VL - 1 UR - https://doi.org/10.1016/S0140-6736(89)90014-7 DO - 10.1016/S0140-6736(89)90014-7 ID - Macdougall1989 ER - TY - JOUR AU - Macdougall, I. C. AU - Roberts, D. E. AU - Coles, G. A. AU - Williams, J. D. PY - 1991 DA - 1991// TI - Clinical pharmacokinetics of epoetin (recombinant human erythropoietin) JO - Clin Pharmacokinet VL - 20 UR - https://doi.org/10.2165/00003088-199120020-00002 DO - 10.2165/00003088-199120020-00002 ID - Macdougall1991 ER - TY - JOUR AU - Ateshakadi, A. AU - Johnson, C. A. AU - Oxton, L. L. AU - Hammond, T. G. AU - Bohenek, W. S. AU - Zimmerman, S. W. PY - 1993 DA - 1993// TI - Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis JO - Am J Kidney Dis VL - 21 UR - https://doi.org/10.1016/S0272-6386(12)80037-0 DO - 10.1016/S0272-6386(12)80037-0 ID - Ateshakadi1993 ER - TY - STD TI - Ashai NI, Paganini EP, Wilson M: Intravenous versus subcutaneous dosing of epoetin: a review of the literature. Am J Kidney Dis. 1993, 23-31. suppl 1 ID - ref23 ER - TY - CHAP PY - 2002 DA - 2002// TI - Committee for Proprietary Medicinal Products BT - Note for Guidance on the Investigation of Bioavailability and Bioequivalence. London ID - ref24 ER - TY - JOUR AU - Yamazaki, C. AU - Watanabe, Y. AU - Sakamoto, N. PY - 1993 DA - 1993// TI - Pharmacokinetic study of recombinant human erythropoietin treatment in pre-dialysis end stage renal disease patients JO - Nippon Jinzo Gakkai Shi VL - 35 ID - Yamazaki1993 ER - TY - JOUR AU - Jensen, J. D. AU - Jensen, L. W. AU - Madsen, J. K. PY - 1994 DA - 1994// TI - The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites JO - Eur J Clin Pharmacol VL - 46 UR - https://doi.org/10.1007/BF00194401 DO - 10.1007/BF00194401 ID - Jensen1994 ER - TY - JOUR AU - Lappin, T. R. J. AU - Rich, I. N. PY - 1996 DA - 1996// TI - Erythropoietin: the first 90 years JO - Clin Lab Haematol VL - 18 UR - https://doi.org/10.1046/j.1365-2257.1996.00172.x DO - 10.1046/j.1365-2257.1996.00172.x ID - Lappin1996 ER - TY - JOUR AU - Lacey, L. F. AU - Keene, O. N. AU - Duquesnoy, C. AU - Bye, A. PY - 1994 DA - 1994// TI - Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies JO - J Pharm Sci VL - 83 UR - https://doi.org/10.1002/jps.2600830219 DO - 10.1002/jps.2600830219 ID - Lacey1994 ER - TY - JOUR AU - Schall, R. AU - Luus, H. G. AU - Steinijans, V. W. AU - Hauschke, D. PY - 1994 DA - 1994// TI - Choice of characteristics and their bioequivalence ranges for the comparison of absorption rates of immediate-release drug formulation JO - Int J Clin Pharmacol and Therapeutics VL - 32 ID - Schall1994 ER - TY - JOUR AU - Basson, R. P. AU - Ghosh, A. AU - Cerimele, B. J. AU - DeSante, K. A. AU - Howey, D. C. PY - 1998 DA - 1998// TI - Why rate of absorption inferences in single dose bioequivalence studies are often inappropriate JO - Pharm Res VL - 15 UR - https://doi.org/10.1023/A:1011974803996 DO - 10.1023/A:1011974803996 ID - Basson1998 ER - TY - JOUR AU - Hauck, W. W. AU - Parekh, A. AU - Lesko, L. J. AU - Chen, M. L. AU - Williams, R. L. PY - 2001 DA - 2001// TI - Limits of 80%–125% for AUC and 70%–143% for Cmax. What is the impact on bioequivalence studies? JO - Int J Clin Pharmacol Ther VL - 39 UR - https://doi.org/10.5414/CPP39350 DO - 10.5414/CPP39350 ID - Hauck2001 ER - TY - JOUR AU - Endrenyi, L. AU - Yan, W. PY - 1993 DA - 1993// TI - Variation of Cmax and Cmax/AUC in investigations of bioequivalence JO - Int J Clin Pharmacol Ther Toxicol VL - 31 ID - Endrenyi1993 ER - TY - JOUR AU - Schall, R. AU - Luus, H. G. PY - 1992 DA - 1992// TI - Comparison of absorption rates in bioequivalence studies of immediate drug formulations JO - Int J Clin Pharmacol Ther Toxicol VL - 30 ID - Schall1992 ER - TY - JOUR AU - Masunaga, H. AU - Takahira, R. AU - Murase, Y. AU - Tsuda, E. AU - Sawai, T. PY - 1991 DA - 1991// TI - Pharmacokinetics and the time course of pharmacodynamics of recombinant human erythropoietin (SNB-5001) JO - Nippon Yakurigaku Zasshi VL - 98 UR - https://doi.org/10.1254/fpj.98.2_143 DO - 10.1254/fpj.98.2_143 ID - Masunaga1991 ER - TY - CHAP AU - Levy, G. ED - Crommelin, D. J. ED - Mida, K. K. PY - 1991 DA - 1991// TI - Pharmacodinamic considerations in bioavailability and bioequivalence assessments BT - Topics in Pharmaceutical Sciences ID - Levy1991 ER - TY - JOUR AU - Reigner, B. G. AU - Williams, P. E. AU - Patel, I. H. AU - Steimer, J. L. AU - Peck, C. AU - van Brummelen, P. PY - 1997 DA - 1997// TI - An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche JO - Clin Pharmacokinet VL - 33 UR - https://doi.org/10.2165/00003088-199733020-00005 DO - 10.2165/00003088-199733020-00005 ID - Reigner1997 ER - TY - JOUR AU - Varlet-Marie, E. AU - Gaudard, A. AU - Audran, M. AU - Gomeni, R. AU - Bressolle, F. PY - 2003 DA - 2003// TI - Pharmacokinetic-pharmacodynamic modeling of recombinant human erythropoietin in athletes JO - Int J Sports Med VL - 24 UR - https://doi.org/10.1055/s-2003-39506 DO - 10.1055/s-2003-39506 ID - Varlet-Marie2003 ER - TY - JOUR AU - Cheung, W. AU - Minton, N. AU - Gunawardena, K. PY - 2001 DA - 2001// TI - Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly JO - Eur J Clin Pharmacol VL - 57 UR - https://doi.org/10.1007/s002280100324 DO - 10.1007/s002280100324 ID - Cheung2001 ER - TY - JOUR AU - Jacquot, C. AU - Ferragu-Haguet, M. AU - Lefebvre, A. AU - Berthelot, J. M. AU - Peterlongo, F. AU - Castaigne, J. P. PY - 1987 DA - 1987// TI - Recombinant erythropoietin and blood pressure JO - Lancet VL - 2 UR - https://doi.org/10.1016/S0140-6736(87)91504-2 DO - 10.1016/S0140-6736(87)91504-2 ID - Jacquot1987 ER - TY - JOUR AU - Klinkmann, H. AU - Wieczorek, L. AU - Scigalla, P. PY - 1993 DA - 1993// TI - Adverse events of subcutaneous recombinant human erythropoietin therapy: results of a controlled multicenter European study JO - Artif Organs VL - 17 UR - https://doi.org/10.1111/j.1525-1594.1993.tb00571.x DO - 10.1111/j.1525-1594.1993.tb00571.x ID - Klinkmann1993 ER - TY - JOUR AU - Chamberlain, P. PY - 2004 DA - 2004// TI - Biogenerics: Europe takes another step forward while the FDA dives for cover JO - Drug Discov Today VL - 9 UR - https://doi.org/10.1016/S1359-6446(04)03215-5 DO - 10.1016/S1359-6446(04)03215-5 ID - Chamberlain2004 ER - TY - JOUR AU - Cheung, W. K. AU - Natarajan, J. AU - Sanders, M. AU - Vercammen, E. PY - 2000 DA - 2000// TI - Comparative pharmacokinetics, safety, and tolerability after subcutaneous administration of recombinant human erythropoietin formulated with different stabilizers JO - Biopharm Drug Dispos VL - 21 UR - https://doi.org/10.1002/bdd.231 DO - 10.1002/bdd.231 ID - Cheung2000 ER - TY - JOUR AU - Casadevall, N. AU - Dupuy, E. AU - Molho-Sabatier, P. AU - Tobelem, G. AU - Varet, B. AU - Mayeux, P. PY - 1996 DA - 1996// TI - Autoantibodies against erythropoietin in a patient with pure red-cell aplasia JO - N Engl J Med VL - 334 UR - https://doi.org/10.1056/NEJM199603073341004 DO - 10.1056/NEJM199603073341004 ID - Casadevall1996 ER - TY - JOUR AU - Bennett, C. L. AU - Luminari, S. AU - Nissenson, A. R. AU - Tallman, M. S. AU - Klinge, S. A. AU - McWilliams, N. AU - McKoy, J. M. AU - Kim, B. AU - Lyons, E. A. AU - Trifilio, S. M. AU - Raisch, D. W. AU - Evens, A. M. AU - Kuzel, T. M. AU - Schumock, G. T. AU - Belknap, S. M. AU - Locatelli, F. AU - Rossert, J. AU - Casadevall, N. PY - 2004 DA - 2004// TI - Pure Red-Cell Aplasia and Epoetin Therapy JO - N Engl J Med VL - 351 UR - https://doi.org/10.1056/NEJMoa040528 DO - 10.1056/NEJMoa040528 ID - Bennett2004 ER - TY - JOUR AU - Wu, G. AU - Wadgymar, A. AU - Wong, G. AU - Ting, R. AU - Nathoo, B. AU - Mendelssohn, D. AU - Pandeya, S. AU - Sapir, D. AU - Tam, P. PY - 2004 DA - 2004// TI - A cross-sectional immunosurveillance study of anti-EPO antibody levels in CRF patients receiving epoetin alfa in 5 Ontario Renal Centers JO - Am J Kidney Dis VL - 44 UR - https://doi.org/10.1053/j.ajkd.2004.04.031 DO - 10.1053/j.ajkd.2004.04.031 ID - Wu2004 ER - TY - STD TI - Epoetin alfa. Mosby's Drug Consult. Edited by: David Nissen. 2005, Mosby Inc. St. Louis, Missouri ID - ref46 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/6/5/prepub UR - http://www.biomedcentral.com/1471-2369/6/5/prepub ID - ref47 ER -